Skip to main content
OpenTrials
Completed

NCT Number: NCT05565742

A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lipoprotein Disorder

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Centro de Investigaciones Metabólicas (CINME), Ciudad Autónoma de Buenos Aire, Buenos Air, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be at least 40 years old at the time of signing the informed consent.
  • Participants with Lp(a) ≥175 nmol/L at screening, measured at the central laboratory
  • Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to screening and randomization and expected to remain on a stable regimen through the end of the Treatment and Assessment Period:
  • lipid-lowering drugs
  • testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone
  • Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.

Male and/or Female

  • Males who agree to use highly effective/effective methods of contraception may participate in this trial.
  • Women not of childbearing potential (WNOCBP) may participate in this trial.

Exclusion criteria

  • Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.
  • Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
  • major surgery
  • coronary, carotid, or peripheral arterial revascularization
  • stroke or transient ischemic attack
  • myocardial infarction or unstable angina
  • acute limb ischemia
  • Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes.
  • Have uncontrolled hypertension

Treatment and study plan

LY3819469

Drug

Administered SC

Placebo

Drug

Administered SC

Primary outcomes

  1. Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180

    Time frame: Baseline, Days 60 - 180

    LPa levels were assessed using Immuno turbidimetric method. Percent change is calculated as: Percent Change=[(Lp(a) at Time Point-Lp(a) at Baseline)/Lp(a) at Baseline]×100 Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment*Time (Type III sum of squares) as post-baseline measures. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

Secondary outcomes

  1. Percent Change From Baseline in Time Averaged Lp(a) Over Days 240-360

    Time frame: Baseline, Days 240 - 360

    LPa levels were assessed using Immuno turbidimetric method. LS mean was determined using MMRM model with log(Lp(a)) - log(Baseline) = log(Baseline) + Treatment + Time + Treatment*Time (Type III sum of squares) as post-baseline measures.. Result presented is after back-transformation. Variance-Covariance structure = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

  2. Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 60, 180

    Time frame: Days 60, 180

    Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (nmol/L) at Days 60, 180 is reported.

  3. Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540

    Time frame: Days 240, 360, and 540

    Percentage of Participants Achieving Lp(a) <125 and <75 Nanomole/Liter (Nmol/L) at Days 240, 360, and 540 is reported.

  4. Percent Change From Baseline in Lp(a)

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

    LS mean was determined using MMRM model with log(Actual Measurement/Baseline) = log (Baseline) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment*Time (Type III sum of squares) as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

  5. Percent Change From Baseline in Apolipoprotein B (ApoB)

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

    LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (<275 nmol/L vs. >=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

  6. Percent Change From Baseline in High-sensitivity C-reactive Protein (hsCRP)

    Time frame: Baseline, Days 60, 180, 240, 360, and 540

    hsCRP is a laboratory analyte that is an indicator of inflammation. Decreases in hsCRP represent reductions in inflammation. LS mean was determined using MMRM model with log (Actual Measurement/Baseline) = log(Baseline) + Baseline Lp(a) stratum (<275 nmol/L vs. >=275 nmol/L) + High Risk CV Stratum (yes/no) + Treatment + Time + Treatment*Time (Type III sum of squares as post-baseline measures. Variance-Covariance structure (Change from Baseline) = Unstructured. Analyses included all participants having non-missing baseline and at least one non-missing post-baseline value of the response variable.

  7. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of LY3819469

    Time frame: Day 1: 0.5 hours, 4-9 hours post-dose; Day 180: 24-36 hours post-dose

    AUC was computed using the population PK model. Therefore, the concentrations are simulated from time 0 to infinity to estimate AUC for each participant. The timeframe reflects the PK timepoints that were collected to develop the population PK. Although this is a multiple dose study, the plasma PK is very short, so AUC0-180days is equivalent to AUC0-infinity.

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Oct 4, 2022
Registry last updated
May 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.